Add Company
Join Now

NervGen Pharma Corp. Revenue and Competitors

License our Company Data API

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • NervGen Pharma Corp.'s estimated annual revenue is currently $1.7M per year.(i)
  • NervGen Pharma Corp.'s estimated revenue per employee is $77,500

Employee Data

  • NervGen Pharma Corp. has 22 Employees.(i)
  • NervGen Pharma Corp. grew their employee count by -4% last year.

NervGen Pharma Corp.'s People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Co-FounderReveal Email/Phone
3
President & CEOReveal Email/Phone
4
Chief Medical OfficerReveal Email/Phone
5
Chief Medical OfficerReveal Email/Phone
6
Chief Financial OfficerReveal Email/Phone
7
Head Clinical OperationsReveal Email/Phone
8
VP, Research and Preclinical DevelopmentReveal Email/Phone
9
VP, Program ManagementReveal Email/Phone
10
Director Research & NVG-291 Project LeaderReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.1M4018%$40MN/A
#2
$0.2M20%N/AN/A
#3
$1.3M17-15%N/AN/A
#4
$2.6M176%N/AN/A
#5
$12.9M835%N/AN/A
#6
$1.9M244%$89.5MN/A
#7
$2.8M186%N/AN/A
#8
$40.3M26021%N/AN/A
#9
$0.9M60%N/AN/A
#10
$0.6M4-20%N/AN/A
Add Company

What Is NervGen Pharma Corp.?

NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing innovative treatments for nervous system damage, due to injury or disease. NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. NVG-291 entered Phase 1 clinical trials in 2021. After completing our Phase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$1.7M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.5M22-15%$9.9M
#2
$2.2M220%N/A
#3
$3.4M225%N/A
#4
$3.2M220%N/A
#5
$3.8M220%N/A